ATTR-CM Access Landscape: Tafamidis, Acoramidis, and Vutrisiran

Transthyretin amyloid cardiomyopathy (ATTR-CM) has transitioned from an underdiagnosed, fatal rare disease to one of the most commercially significant, high-cost franchises in cardiology. The disease is characterized by the misfolding of the transthyretin (TTR) protein—either due to a genetic mutation (hereditary ATTR, or hATTR) or aging (wild-type ATTR, or wtATTR). These misfolded proteins aggregate into amyloid fibrils that deposit in the myocardium, leading to progressive restrictive cardiomyopathy, heart failure, and death.

Historically, treatment was limited to supportive heart failure therapies and liver or heart transplantation. In May 2019, the FDA approved Pfizer’s Vyndaqel and Vyndamax (tafamidis), establishing the first disease-modifying therapies for ATTR-CM. The success of tafamidis demonstrated a major market, prompting a wave of drug development.

In 2026, the ATTR landscape is defined by three major therapeutic options for cardiomyopathy, alongside several silencers approved for the polyneuropathy (hATTR-PN) indication. Navigating this landscape requires understanding the clinical differences between "stabilizers" and "silencers," verifying reimbursement codes and Wholesale Acquisition Costs (WAC), navigating strict prior authorization (PA) criteria, and preparing for the December 2026 composition-patent cliff of tafamidis.

For comparative analyses of adjacent specialty cardiovascular and rare disease access landscapes, see the PAH access landscape detailing sotatercept access, the hemophilia access landscape for high-cost billing and coding structures, the Casgevy access guide for Medicaid gene therapy contracting, and the AstraZeneca portfolio dossier for coverage of eplontersen. For the underlying methodology on patent timelines, see the Orange Book market-exclusivity analysis.

---

Which drugs are FDA-approved for ATTR-CM and hATTR-PN, and how do stabilizers and silencers differ?

Cardiologists and formulary managers must distinguish between drugs approved for transthyretin amyloid cardiomyopathy (ATTR-CM) and those approved for hereditary transthyretin amyloid polyneuropathy (hATTR-PN). While some patients exhibit overlapping symptoms, payers enforce strict boundaries based on the FDA-approved indications.

The six disease-modifying agents in this class are categorized by their mechanism of action:

1. Transthyretin Stabilizers (Tafamidis, Acoramidis)

Stabilizers bind to the thyroxine-binding sites of the TTR tetramer, preventing it from dissociating into unstable monomers, which is the rate-limiting step in amyloid fibril formation.

• Tafamidis meglumine / Tafamidis (Vyndaqel / Vyndamax, Pfizer): Approved on May 3, 2019, for the treatment of cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis in adults to reduce cardiovascular mortality and cardiovascular-related hospitalization. Vyndaqel is dosed as 80 mg orally daily (four 20 mg capsules), while Vyndamax is a single 61 mg oral capsule daily, developed for improved patient convenience and bioequivalence.
• Acoramidis hydrochloride (Attruby, BridgeBio): Approved on November 22, 2024, for ATTR-CM. Acoramidis was designed as a high-affinity stabilizer that mimics a naturally occurring protective TTR mutation (T119M), achieving near-complete (at least 90%) stabilization of wild-type and variant TTR at trough concentrations. It is dosed orally as 800 mg twice daily.

2. Transthyretin Silencers (Vutrisiran, Patisiran, Eplontersen, Inotersen)

Silencers utilize RNA interference (RNAi) or antisense oligonucleotides (ASOs) to target and degrade TTR messenger RNA (mRNA) in the liver, which is the primary site of TTR synthesis. By blocking mRNA translation, these agents reduce the production of both wild-type and mutant TTR proteins.

• Vutrisiran sodium (Amvuttra, Alnylam): Originally approved on June 13, 2022, for the polyneuropathy of hATTR in adults. On March 20, 2025, vutrisiran received FDA approval for the treatment of ATTR-CM, based on the HELIOS-B phase 3 trial. It is administered as a 25 mg subcutaneous injection once every three months.
• Patisiran sodium (Onpattro, Alnylam): Approved on August 10, 2018, for the polyneuropathy of hATTR. It is administered as an intravenous (IV) infusion once every three weeks. Despite the APOLLO-B trial showing positive cardiovascular signals, the FDA declined to expand its indication to ATTR-CM in late 2023, citing marginal clinical benefit relative to the burden of IV infusion, meaning patisiran remains indicated for polyneuropathy only.
• Eplontersen (Wainua, AstraZeneca/Ionis): Approved on December 21, 2023, for the polyneuropathy of hATTR. It is a ligand-conjugated antisense oligonucleotide (LICA) administered as a 45 mg subcutaneous injection once monthly. Its clinical trial for cardiomyopathy (CARDIO-TTRansform) is ongoing, with an FDA decision for the ATTR-CM indication pending.
• Inotersen (Tegsedi, Sobi/Ionis): Approved on October 5, 2018, for the polyneuropathy of hATTR. It is an antisense oligonucleotide administered as a weekly subcutaneous injection (284 mg). Because of safety concerns (thrombocytopenia and glomerulonephritis), Tegsedi requires monthly platelet and renal monitoring under a restricted REMS program, limiting its real-world access.

The table below summarizes the approved indications and clinical trial endpoints for these six agents:

---

What do the ATTR agents cost, and how are they billed (HCPCS J0225, J0222, and oral pharmacy benefit)?

The financial footprint of ATTR therapies represents a significant challenge for healthcare systems. When tafamidis was approved in 2019, its WAC of approximately $225,000 per year (later rising to approximately $268,000 per year or $22,350 per month) made it the most expensive cardiovascular drug ever approved in the United States.

Reimbursement pathways and billing codes differ depending on the route of administration:

1. Oral Stabilizers (Pharmacy Benefit)

Tafamidis (Vyndaqel/Vyndamax) and acoramidis (Attruby) are oral medications distributed through limited specialty pharmacy networks. They are billed under the pharmacy benefit (Medicare Part D or commercial pharmacy benefits) and do not have permanent HCPCS J-codes.

• Tafamidis WAC: Approximately $268,000 per year. The Institute for Clinical and Economic Review (ICER) evaluated tafamidis in its 2020 report and concluded that its cost-effective value-based price is between $13,600 and $39,000 per year—representing an 85% to 95% discount from the list price.
• Acoramidis WAC: BridgeBio launched Attruby at a WAC of $18,759.12 per 28-day supply, which translates to approximately $244,539 per year (the sponsor raised the WAC to $19,790 per 28-day supply, roughly $257,900 per year, in January 2026). By pricing Attruby just below Vyndamax, the sponsor aims to secure preferred formulary placement while maintaining premium specialty pricing.

2. Silencers (Benefit Depends on Route of Administration)

Vutrisiran (Amvuttra) and patisiran (Onpattro) are administered by a healthcare provider—subcutaneous injection and intravenous infusion, respectively—so they are billed under the medical benefit (Medicare Part B or commercial medical benefits) using permanent HCPCS J-codes. Eplontersen (Wainua) is a self-injected autoinjector and therefore runs through the pharmacy benefit with no product-specific J-code:

• Vutrisiran (Amvuttra): Billed under HCPCS code J0225 (Injection, vutrisiran, 1 mg). The standard dose is 25 mg subcutaneously every three months, using NDC 71336-1003. Its WAC is approximately $119,300 per dose, which translates to an annual WAC of $477,200.
• Patisiran (Onpattro): Billed under HCPCS code J0222 (Injection, patisiran, 0.1 mg). Dosed intravenously every three weeks. The WAC is approximately $10,150 per vial, resulting in an annual cost of $350,000 to $450,000 depending on the patient's weight.
• Eplontersen (Wainua): A once-monthly 45 mg subcutaneous autoinjector designed for patient self-administration (NDC 00310-9400-01). Because it is self-injected, it is dispensed under the pharmacy benefit and carries no product-specific HCPCS J-code (major payer policies, including Aetna's ATTR bulletin, list "no specific code" for Wainua; provider-supplied doses are processed under an unclassified code such as J3490/J3590). AstraZeneca lists Wainua at approximately $42,800 per 45 mg dose, or roughly $514,000 per year. Note that Wainua is FDA-approved for hATTR-PN only; its ATTR-CM application (CARDIO-TTRansform) remains pending, so it is not yet a covered ATTR-CM option.

The table below outlines the billing codes, NDC numbers, and annual list prices:

---

What prior-authorization criteria do payers apply to ATTR-CM therapy?

Because of the high cost of these medications, major commercial payers (such as UnitedHealthcare, Aetna, and Cigna) and state Medicaid plans enforce strict prior authorization (PA) criteria. Access teams must document compliance with each of the following requirements:

1. Prescriber Restrictions

Coverage policies limit prescribing to cardiologists, neurologists, or physicians affiliated with a specialized amyloidosis center.

2. Objective Diagnostic Confirmation

Payers require documentation of TTR amyloid deposits. This must be established through:

• Genetic Testing: Documentation of a pathogenic TTR mutation (e.g., V122I, T60A, or V30M) confirming hereditary ATTR (hATTR); OR
• Non-Invasive Diagnostic Scintigraphy: a technetium-99m pyrophosphate ($^{99m}Tc$-PYP) or technetium-99m 3,3-diphosphono-1,2-propanodicarboxylic acid ($^{99m}Tc$-DPD) scintigraphy demonstrating Grade 2 or 3 myocardial uptake, in the absence of a monoclonal gammopathy (established via negative serum/urine immunofixation and free light chain assays); OR
• Biopsy Confirmation: Tissue biopsy (myocardial, fat pad, or salivary gland) demonstrating Congo Red positive amyloid deposits with apple-green birefringence under polarized light, with mass spectrometry or immunohistochemistry confirming the transthyretin precursor protein.

3. Baseline Severity Gating

Patients must exhibit functional impairment, typically defined as New York Heart Association (NYHA) Class I, II, or III heart failure. Payers exclude patients with NYHA Class IV heart failure, as clinical trials did not demonstrate benefit in patients with end-stage disease. Additionally, some plans require baseline assessment of a six-minute walk distance (6MWD) or cardiac biomarkers (NT-proBNP).

4. Exclusions and Combination Restrictions

• No Dual Therapy: Payers strictly prohibit the concurrent use of a TTR stabilizer (tafamidis, acoramidis) with a TTR silencer (vutrisiran, patisiran, eplontersen). No clinical evidence supports combination therapy, and the annual cost of dual treatment would exceed $700,000.
• Indication Checks: Payers will deny vutrisiran (Amvuttra) or eplontersen (Wainua) if the patient's records list cardiomyopathy without polyneuropathy, unless the drug has received the specific FDA CM indication (vutrisiran has the approval; eplontersen does not).
• Contraindications: For stabilizers, patients must not have had a prior liver transplant, as the new liver secretes wild-type TTR, altering the disease biology.

5. Reauthorization and Renewal Gating

Initial approvals are typically granted for 12 months. Reauthorization requires the physician to document that the patient has experienced clinical benefit, defined as:

• Maintenance of, or slow decline in, functional capacity (6MWD or NYHA class).
• Stabilization of cardiac biomarkers (NT-proBNP or BNP) relative to the natural history of the disease.
• No progression to NYHA Class IV heart failure.
• Documented adherence to the prescribed regimen.

---

What does the FAERS post-marketing profile show for the ATTR disease-modifying agents?

To evaluate the real-world safety profile of these therapies, we analyzed post-marketing reports in the openFDA FAERS database. Across the six disease-modifying agents (tafamidis, acoramidis, vutrisiran, patisiran, eplontersen, and inotersen), the database contains 21,497 reports current through June 8, 2026.

Seriousness and the Advanced-Heart-Failure Mortality Baseline

Of the 21,497 reports in the ATTR cohort, 16,448 reports (76.5%) are classified as serious, and 6,502 reports (30.2%) document a fatal outcome. Death is the single most frequently reported MedDRA term in the cohort, with 4,865 specific reports.

This high death share (30.2%) is a critical pharmacovigilance finding that requires careful clinical interpretation. It does not indicate that ATTR-CM medications are highly toxic or cause death. Rather, it represents a population artifact of the underlying disease:

1. Late-Stage Diagnosis: Patients with ATTR-CM are typically diagnosed late in their disease course, often after years of unexplained heart failure. Many are elderly (median age of onset for wild-type ATTR-CM is over 75 years) with significant cardiac remodeling.
2. High Baseline Mortality: The natural history of untreated ATTR-CM carries a median survival of only 2 to 3.5 years from diagnosis. Despite disease-modifying therapy, a significant proportion of patients succumb to progressive heart failure or sudden cardiac death.
3. Spontaneous Reporting Bias: In a high-cost, specialty-managed patient population, physicians and specialty pharmacies monitor patients closely. Any death in a patient receiving a $268,000-per-year therapy is reported to the manufacturer's safety database, inflating the fatal outcome share relative to less closely monitored therapies.

Reporting Trends and Agent Leaders

Post-marketing reports peaked in 2025 with 4,141 reports, reflecting the expansion of the treated population following the approvals of acoramidis and vutrisiran for cardiomyopathy.

The table below details the report counts by specific active substances, highlighting the dominance of the first-in-class stabilizer:

• Tafamidis (generic string match): 10,744 reports
• Tafamidis Meglumine (Vyndaqel salt): 4,443 reports
• Note on Tafamidis Overlap: Because Vyndaqel is formulated as the meglumine salt and Vyndamax as the free acid, these two strings represent the same drug. These counts must be analyzed together, representing a combined footprint of over 15,000 reports.
• Patisiran Sodium (Onpattro): 2,605 reports
• Vutrisiran Sodium (Amvuttra): 2,046 reports
• Acoramidis Hydrochloride (Attruby): 246 reports
• Eplontersen (Wainua): 160 reports

Acoramidis (246 reports) and eplontersen (160 reports) show small footprints due to their recent launch dates.

Gender Skew and Indication Match

A key demographic finding is the gender distribution: 11,854 reports (55.1%) involve male patients, compared to only 3,176 reports (14.8%) involving female patients (with the remainder unspecified). This male predominance is consistent with the epidemiology of wild-type ATTR-CM, which is clinically diagnosed in males over females at a ratio of approximately 10:1.

The top indications in the cohort confirm that the data captures the target patient population:

• Cardiac Amyloidosis: 5,202 reports
• Hereditary Neuropathic Amyloidosis: 4,226 reports
• Amyloidosis: 3,420 reports
• Acquired ATTR Amyloidosis (wild-type): 1,187 reports

The top reported adverse events, other than death, are cardiac failure (1,229 reports), dyspnea (1,108 reports), fatigue (992 reports), falls (783 reports), and atrial fibrillation (608 reports). These terms reflect the progression of advanced heart failure and amyloid neuropathy (orthostatic hypotension and muscle weakness leading to falls) rather than drug-induced toxicities.

---

When does tafamidis lose exclusivity, and how does that reshape access?

The primary access inflection point in the ATTR-CM category is the expiration of regulatory exclusivity and patent protection for tafamidis. Because Vyndaqel and Vyndamax are oral small molecules, their loss of exclusivity will allow generic manufacturers to submit Abbreviated New Drug Applications (ANDAs), introducing low-cost generic options.

To understand this timeline, we analyzed the FDA Orange Book patent and exclusivity records (current to the local database snapshot on July 8, 2026) for Pfizer’s NDAs:

• Vyndaqel (Tafamidis Meglumine, NDA 211996): Approved May 3, 2019.
• Vyndamax (Tafamidis, NDA 212161): Approved May 3, 2019.

The Exclusivity Timeline

1. Orphan Drug Exclusivity (ODE-237): Under the Orphan Drug Act, the FDA granted tafamidis seven years of marketing exclusivity for the ATTR-CM indication. This exclusivity expired on May 3, 2026.
2. Core Composition Patents: Pfizer listed two core patents in the Orange Book covering the active chemical compound:
   • US Patent 7,214,695 ('695 patent): Flagged as drug substance and drug product. It expires on December 19, 2026.
   • US Patent 7,214,696 ('696 patent): A method-of-use patent (use code U-2524, representing the treatment of transthyretin amyloidosis). It also expires on December 19, 2026.
3. The Secondary Patent Barrier: Pfizer listed a later formulation patent in the Orange Book:
   • US Patent 9,770,441 ('441 patent): Covers the solid oral dosage form. This patent does not expire until August 31, 2035.

The table below illustrates the patent and exclusivity landscape for the oral stabilizers:

Access Strategy After December 2026

The expiration of the core composition patents on December 19, 2026, marks the end of Pfizer's monopoly on the active compound. However, the presence of the '441 patent (extending to 2035) means that immediate generic entry is not guaranteed.

Generic manufacturers have two pathways:

1. Paragraph IV Certification: ANDA applicants can certify that the '441 patent is invalid or will not be infringed by their generic formulation. This typically triggers patent litigation, which can delay generic entry by up to 30 months.
2. Formulation Workarounds: Generic manufacturers can develop alternative formulations that do not infringe the '441 patent, allowing them to launch immediately after December 19, 2026.
3. Patent Settlements: Brand and generic manufacturers frequently settle litigation, allowing generic entry at an agreed date prior to patent expiration (often matching the core patent expiry or shortly thereafter).

Impact on the ATTR-CM Category

The availability of generic tafamidis will transform market access:

• Payer Restrictions: Payers will likely implement "generic first" step-therapy edits. Patients will be required to try and fail generic tafamidis before receiving branded Attruby (acoramidis) or Amvuttra (vutrisiran).
• Category Pricing Compression: To remain competitive, BridgeBio (Attruby) and Alnylam (Amvuttra) will face pressure to offer higher rebates to PBMs, compressing their net prices.
• Silencer Positioning: The TTR silencer class will be positioned as a second-line option for patients who experience disease progression on generic stabilizers.

---

FAQs

Is acoramidis (Attruby) better than tafamidis (Vyndamax), and is it cheaper?

In the phase 3 ATTRibute-CM trial, acoramidis demonstrated high rates of TTR stabilization (at least 90% at trough) and led to an 81% survival rate at 30 months compared to 74% for placebo. Because there are no head-to-head clinical trials comparing acoramidis and tafamidis, we cannot definitively state that one is superior.

In terms of cost, Attruby was launched at a WAC of $244,539 per year, which is approximately 9% lower than Vyndamax ($268,200 per year). However, the actual out-of-pocket cost for patients depends on insurance coverage and manufacturer co-pay assistance.

Is patisiran (Onpattro) approved for the heart, or only for ATTR polyneuropathy?

Patisiran (Onpattro) is FDA-approved for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis (hATTR-PN) only. The FDA declined Alnylam's application to expand patisiran's indication to ATTR-CM in late 2023, determining that the treatment benefit did not justify the burden of its intravenous administration. Patients with cardiac amyloidosis requiring an RNAi silencer are typically prescribed vutrisiran (Amvuttra), which is approved for ATTR-CM and administered subcutaneously.

When will a generic tafamidis be available?

The core composition patents for tafamidis expire on December 19, 2026. While generic manufacturers can seek FDA approval after this date, Pfizer's secondary formulation patent ('441 patent) extends to August 31, 2035. Generic entry will depend on whether ANDA applicants successfully challenge the secondary patent or negotiate settlements. Payers are already preparing for generic availability in 2027 by designing step-therapy policies.

---

Sources

• US FDA, Purple Book Database of Licensed Biological Products (snapshot current to July 8, 2026). https://www.fda.gov/vaccines-blood-biologics/purple-book-database-license-biological-products
• US FDA, Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations (local database snapshot current to July 8, 2026). https://www.accessdata.fda.gov/scripts/cder/ob/index.cfm
• US FDA, Vyndaqel and Vyndamax (tafamidis meglumine / tafamidis) prescribing information (NDA 211996 and NDA 212161, initial approval May 3, 2019). https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211996s000lbl.pdf
• US FDA, Attruby (acoramidis hydrochloride) prescribing information (NDA 216540, approval November 22, 2024). https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/216540s000lbl.pdf
• US FDA, Amvuttra (vutrisiran sodium) prescribing information (BLA 761250, ATTR-CM indication approved March 20, 2025). https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/761250s000lbl.pdf
• US FDA, Onpattro (patisiran sodium) prescribing information (BLA 761042, initial approval August 10, 2018). https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/761042s000lbl.pdf
• Institute for Clinical and Economic Review (ICER), Disease-Modifying Therapies for Transthyretin Amyloid Cardiomyopathy: Final Evidence Report and 12-Month Check-Up (published 2024-2025). https://icer.org/wp-content/uploads/2025/12/ICER_ATTR-CM_Final-Report_10212024_12MonthCheckUp.pdf
• UnitedHealthcare, Commercial Medical Benefit Drug Policy: RNA-Targeted Therapies for Hereditary Transthyretin Amyloidosis (effective April 1, 2026). https://www.uhcprovider.com/content/dam/provider/docs/public/policies/medicaid-comm-plan/rna-targeted-therapies-cs.pdf
• Blue Shield of California, Medical Benefit Drug Policy: Vutrisiran (Amvuttra) Prior Authorization Criteria (revised 2025). https://www.blueshieldca.com/provider/content/dam/bsc/provider/us/en/documents/medical-policies/Vutrisiran-Amvuttra.pdf
• openFDA, FAERS Database API and raw CSV download files (data snapshot current to export dated June 8, 2026; containing 20,328,575 total reports). https://open.fda.gov/data/faers/
• Alnylam Pharmaceuticals, Amvuttra Billing and Coding Guide for Healthcare Providers (HCPCS J0225, NDC 71336-1003, 25 mg/0.5 mL prefilled syringe). https://www.alnylamassist.com/sites/default/files/pdfdownloads/amvuttra-vutrisiran-billing-coding-guide-for-physicians.pdf
• BridgeBio Pharma, BridgeBio Announces FDA Approval of Attruby (acoramidis) for ATTR-CM (November 22, 2024). https://investor.bridgebio.com/news/news-details/2024/attruby-acoramidis-a-near-complete-ttr-stabilizer-90-approved-by-fda-to-reduce-cardiovascular-death-and-cardiovascular-related-hospitalization-in-attr-cm-patients-11-22-2024/default.aspx
• Alnylam Pharmaceuticals, Alnylam Announces FDA Approval of Amvuttra (vutrisiran) for the Treatment of ATTR-CM (March 20, 2025). https://investors.alnylam.com/press-release?id=28831
• Maurer MS, et al. Tafamidis Treatment for Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-ACT). N Engl J Med. 2018;379:1007-1016. (PMID: 30145929) https://pubmed.ncbi.nlm.nih.gov/30145929
• Gillmore JD, et al. Efficacy and Safety of Acoramidis in Transthyretin Amyloid Cardiomyopathy (ATTRibute-CM). N Engl J Med. 2024;390:132-142. (PMID: 38197816) https://pubmed.ncbi.nlm.nih.gov/38197816
• AstraZeneca, Wainua (eplontersen) Cost and Affordability (US list price $42,830.83 per 45 mg once-monthly dose; self-administered subcutaneous autoinjector, pharmacy benefit). https://www.wainua.com/cost-and-affordability
• Aetna, Clinical Policy Bulletin 0939: Transthyretin-Mediated (ATTR) Amyloidosis (HCPCS J0222 patisiran, J0225 vutrisiran; "no specific code" for Vyndamax/Vyndaqel, Wainua/eplontersen, and Attruby/acoramidis). https://www.aetna.com/cpb/medical/data/900_999/0939.html